Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Summary

This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be randomized to one of the three following mobilization regimens: Arm A = VELCADE, CYCLOPHOSPHAMIDE, \& G-CSF Arm B = VELCADE \& G-CSF Arm C = CYCLOPHOSPHAMIDE \& G-CSF Arm D = PLERIXAFOR \& G-CSF Arm E = PLERIXAFOR, VELCADE, \& G-CSF

Timeline

Start

2011-03

Primary completion

2019-02-04

Completion

2019-02-04

Outcome

Missed primary endpoint

registry analysis (superiority test); Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF vs Arm C: CYCLOPHOSPHAMIDE & G-CSF; p = 0.90 NCT01146834 ↗

Drugs

Indications